Targeted therapy for lung cancer: Types and side effects

Targeted therapy for lung cancer sounds a little like science fiction: find the tumor’s weak spot, aim a drug at it, and tell cancer cells to stop acting like they own the place. In real oncology clinics, of course, it is more complicated than that. Still, targeted therapy has changed the treatment story for many people with non-small cell lung cancer, especially those whose tumors carry specific genetic changes such as EGFR, ALK, ROS1, BRAF, MET, RET, NTRK, KRAS, or HER2.

Unlike traditional chemotherapy, which attacks fast-growing cells broadly, targeted therapy is designed to interfere with specific signals that help cancer grow, divide, build blood supply, or spread. That does not mean it is “easy treatment” or side-effect free. It means treatment is more personalized. Think of chemotherapy as a citywide power outage and targeted therapy as cutting the suspicious wire behind the villain’s secret lair. Both can be useful; one is simply more specific.

This guide explains the major types of targeted therapy for lung cancer, why biomarker testing matters, what side effects may happen, and how patients and caregivers can prepare for the real-world experience of living with targeted treatment.

What is targeted therapy for lung cancer?

Targeted therapy is a cancer treatment that uses drugs to block specific molecules involved in cancer growth. In lung cancer, these targets are often abnormal proteins created by gene mutations, gene fusions, or other changes inside the tumor. When a cancer cell depends heavily on one abnormal signal, doctors sometimes call that change a “driver mutation” because it helps drive the cancer forward.

Most targeted therapies for lung cancer are used in non-small cell lung cancer, or NSCLC, which is the most common category of lung cancer. Some are pills taken at home, while others are intravenous infusions given in a cancer center. Targeted therapy may be used for advanced or metastatic lung cancer, and in some cases it may also be used before or after surgery depending on the stage, mutation, and treatment plan.

The big idea is simple: test the tumor, find the target, choose the matching treatment. The hard part is that lung cancer is not one disease wearing one jacket. It is more like a crowded airport terminal of different tumor subtypes, each with its own travel plans, delays, and suspicious carry-on bags.

Why biomarker testing comes first

Before starting targeted therapy, doctors usually order biomarker testing, also called molecular testing, genomic testing, or next-generation sequencing. This testing looks for genetic changes in the cancer cells that may match an approved targeted drug or a clinical trial.

Testing may be done on tissue from a biopsy or surgery. Sometimes doctors also use a liquid biopsy, a blood test that searches for tumor DNA circulating in the bloodstream. Tissue testing remains very important because blood tests may miss some changes, but liquid biopsy can be helpful when tissue is limited or when quick information is needed.

For advanced NSCLC, broad biomarker testing may look for changes such as EGFR mutations, ALK rearrangements, ROS1 fusions, BRAF V600E mutations, MET exon 14 skipping, RET fusions, NTRK fusions, KRAS G12C mutations, HER2 alterations, and other emerging markers. PD-L1 testing may also be done to guide immunotherapy decisions, although immunotherapy is not the same as targeted therapy.

Patients should feel comfortable asking, “Has my tumor had comprehensive biomarker testing?” It is not a rude question. It is a practical one, like asking whether the mechanic checked the engine before replacing the tires.

Main types of targeted therapy for lung cancer

EGFR-targeted therapy

EGFR stands for epidermal growth factor receptor. Certain EGFR mutations can act like a stuck accelerator pedal, telling lung cancer cells to keep growing. EGFR-targeted drugs, often called EGFR tyrosine kinase inhibitors, are designed to block that signal.

Common EGFR-targeted medicines include osimertinib, erlotinib, afatinib, dacomitinib, and other drugs used in selected situations. Osimertinib is widely used for common EGFR mutations such as exon 19 deletions and exon 21 L858R. Some less common EGFR mutations require different strategies. EGFR exon 20 insertion mutations, for example, may be treated with medicines such as amivantamab-based therapy or other newer targeted options depending on the exact situation and current approval status.

Common side effects of EGFR therapy include acne-like rash, dry skin, itching, diarrhea, mouth sores, nail inflammation, fatigue, and appetite changes. Rare but serious risks may include lung inflammation, heart rhythm changes, eye problems, or reduced heart function with certain drugs. The rash may be annoying, but it is not “just cosmetic.” Early skin care can prevent painful cracks, infections, and the feeling that your face has declared independence.

ALK inhibitors

ALK-positive lung cancer happens when the ALK gene becomes rearranged and creates an abnormal growth signal. ALK inhibitors can produce strong and sometimes long-lasting responses in people whose tumors carry this change.

Examples include alectinib, brigatinib, lorlatinib, crizotinib, and ceritinib. These medicines differ in how well they enter the brain, their side-effect profiles, and where they fit in the treatment sequence. Brain protection matters because ALK-positive lung cancer can spread to the central nervous system.

Possible side effects include nausea, diarrhea, constipation, swelling in the hands or feet, fatigue, muscle aches, liver enzyme changes, vision changes, slowed heart rate, lung inflammation, and nerve symptoms. Lorlatinib can also affect cholesterol, triglycerides, mood, memory, sleep, or thinking in some patients. That does not mean everyone will suddenly forget where they put the car keysbut it does mean new cognitive or emotional changes deserve a call to the oncology team.

ROS1-targeted therapy

ROS1 fusions are less common than EGFR or KRAS changes, but they are important because they can be highly treatable. Drugs such as crizotinib, entrectinib, and repotrectinib may be used for ROS1-positive NSCLC.

Side effects vary by drug but may include dizziness, fatigue, nausea, swelling, diarrhea, constipation, vision changes, taste changes, liver enzyme abnormalities, and nerve-related symptoms. Some ROS1 medicines can cause dizziness or balance issues, so patients should report falls, severe lightheadedness, or anything that makes walking feel like a low-budget carnival ride.

BRAF and MEK targeted therapy

Some lung cancers carry a BRAF V600E mutation. In this setting, doctors may use a combination that blocks both BRAF and MEK proteins, such as dabrafenib plus trametinib, or other approved combinations depending on the patient’s treatment history and local practice.

Side effects can include fever, chills, fatigue, nausea, diarrhea, rash, joint pain, swelling, high blood pressure, and changes in liver tests. Fever is especially important because it can become intense and may require holding medicine, adjusting doses, or adding supportive care. Patients should not try to “tough it out” like a hero in a disaster movie. Oncology teams actually want to hear about fevers early.

MET inhibitors

MET exon 14 skipping is a molecular change that can make cancer cells grow and survive. MET inhibitors such as capmatinib and tepotinib may be options for patients whose tumors have this alteration.

Common side effects include swelling, especially in the legs or feet, nausea, fatigue, appetite loss, vomiting, shortness of breath, and changes in kidney or liver blood tests. Swelling can be more than a nuisance. Shoes may stop fitting, ankles may look like they are auditioning for a balloon animal contest, and walking can become uncomfortable. Compression, elevation, dose adjustment, and careful evaluation may help, but patients should ask before trying fixes on their own.

RET inhibitors

RET fusions are another targetable driver in NSCLC. RET inhibitors such as selpercatinib and pralsetinib are designed to block the abnormal RET signal.

Possible side effects include dry mouth, diarrhea or constipation, fatigue, high blood pressure, swelling, liver enzyme changes, bleeding risk, changes in electrolytes, and rarely lung inflammation. Because high blood pressure may develop quietly, home blood pressure checks can be useful. Blood pressure is sneaky; it does not always announce itself with dramatic music.

NTRK fusion therapy

NTRK fusions are rare in lung cancer, but when present, they may be treated with TRK inhibitors such as larotrectinib or entrectinib. These drugs are often discussed as “tumor-agnostic” therapies because they target the fusion across different cancer types, not only lung cancer.

Side effects may include fatigue, dizziness, weight gain, nausea, constipation or diarrhea, liver enzyme changes, swelling, and neurologic symptoms. Because these drugs can affect balance or coordination, patients should report new dizziness, confusion, or trouble walking.

KRAS G12C inhibitors

KRAS was once considered a very difficult targetbasically the “good luck with that” gene of oncology. That changed with the development of KRAS G12C inhibitors. For eligible patients with previously treated KRAS G12C-mutated NSCLC, medicines such as sotorasib and adagrasib may be options.

Common side effects include diarrhea, nausea, vomiting, fatigue, muscle or joint pain, cough, decreased appetite, and liver enzyme elevations. Serious liver irritation and lung inflammation can occur, so regular blood tests and symptom reporting are important. Patients should tell their care team about all medicines and supplements because drug interactions can matter.

HER2-targeted therapy

Some NSCLC tumors have HER2 mutations or other HER2 alterations. HER2-directed treatment may include antibody-drug conjugates such as trastuzumab deruxtecan, and newer HER2-targeted drugs continue to expand the field. Treatment choice depends on the exact HER2 alteration, prior therapies, overall health, and current approvals.

Side effects can include nausea, fatigue, low blood counts, hair thinning, appetite changes, and liver test abnormalities. A serious risk with some HER2-directed treatments is interstitial lung disease or pneumonitis, which can cause cough, fever, or shortness of breath. Because lung cancer patients may already have breathing symptoms, new or worsening respiratory changes should be treated as important, not shrugged off as “probably nothing.”

Anti-angiogenic therapy

Some targeted drugs do not attack a mutation inside the cancer cell. Instead, they target the tumor’s blood supply. Tumors need blood vessels to bring oxygen and nutrients, and anti-angiogenic drugs interfere with that process. Bevacizumab and ramucirumab are examples used in certain lung cancer settings, often with chemotherapy or other treatments.

Side effects may include high blood pressure, bleeding, blood clots, protein in the urine, delayed wound healing, headache, fatigue, and rarely serious bleeding or gastrointestinal perforation. These drugs are not right for everyone, especially patients with certain bleeding risks or recent surgery.

Common side effects of targeted therapy

Side effects depend on the drug, dose, combination, and individual patient. Some people feel quite well on targeted therapy for long periods. Others need dose changes, treatment breaks, or extra medications to manage symptoms. The goal is not to win a suffering contest. The goal is to treat cancer while preserving as much daily life as possible.

Skin, nail, and hair changes

Rash is especially common with EGFR-targeted drugs. It may look like acne, but standard acne products can be too harsh. Dry skin, itching, sun sensitivity, cracked fingertips, scalp irritation, and painful nail folds may also occur. Gentle cleansers, fragrance-free moisturizers, sunscreen, topical medicines, oral antibiotics, and early dermatology support can make a major difference.

Digestive side effects

Diarrhea, nausea, vomiting, constipation, mouth sores, and appetite loss are common across several targeted therapies. Persistent diarrhea can cause dehydration and electrolyte problems. Patients should ask in advance which anti-diarrheal or anti-nausea medicines are safe to use, because waiting until symptoms are severe is like waiting until the kitchen is on fire before looking for the extinguisher.

Fatigue

Fatigue can be caused by the cancer, treatment, anemia, poor sleep, dehydration, pain, stress, or other medical conditions. It is one of the most common and frustrating side effects because it can be invisible to everyone else. Light activity, nutrition support, sleep routines, and treating reversible causes may help, but severe or sudden fatigue should be reported.

Liver, kidney, and blood test changes

Many targeted therapies can change liver enzymes, kidney markers, blood counts, cholesterol, electrolytes, or other lab values. This is why regular blood work is part of treatment. Patients may feel perfectly fine while a lab value is waving a tiny red flag. Skipping labs is not a great place to express your rebellious side.

Lung inflammation

A rare but serious side effect of several targeted therapies is pneumonitis or interstitial lung disease. Symptoms may include new cough, worsening shortness of breath, chest discomfort, or fever. Because these symptoms can overlap with infection, cancer progression, or other lung problems, the oncology team should evaluate them quickly.

Heart and blood pressure effects

Some targeted therapies can affect heart rhythm, heart pumping function, cholesterol levels, or blood pressure. Patients may need electrocardiograms, echocardiograms, blood pressure checks, or medication adjustments. Report fainting, chest pain, severe dizziness, racing heartbeat, or sudden swelling right away.

How doctors choose the right targeted therapy

Choosing targeted therapy is not based on one factor alone. Doctors consider the cancer type, stage, biomarker results, symptoms, whether cancer has spread to the brain, prior treatments, other medical conditions, patient preferences, side-effect risks, insurance coverage, and clinical trial options.

For example, two patients may both have EGFR-mutated lung cancer, but one may need a medicine with strong brain activity, while another may need a strategy based on a less common EGFR mutation. A patient with high blood pressure and bleeding risk may not be a good candidate for certain anti-angiogenic drugs. A patient with liver disease may need extra caution with medicines known to affect liver enzymes.

Resistance is another key issue. Targeted therapy can work very well, but cancer cells may eventually find a detour around the blocked pathway. When cancer grows again, doctors may repeat biopsy or liquid biopsy to look for resistance mutations. Sometimes the next treatment is another targeted therapy. Sometimes it is chemotherapy, immunotherapy, radiation, local treatment to a growing spot, or a clinical trial.

Practical experiences: what targeted therapy often feels like

In real life, targeted therapy is both hopeful and oddly ordinary. Many patients are surprised that a powerful cancer medicine may arrive as tablets in a bottle or a scheduled infusion that looks less dramatic than expected. The first few weeks often involve learning a new routine: when to take the drug, whether food matters, which medicines to avoid, how often labs are needed, and what symptoms deserve a phone call.

One common experience is the emotional whiplash of waiting for biomarker results. Patients may hear, “We need more testing before choosing treatment,” and feel as if nothing is happening. In reality, that waiting period can be medically important. Starting the wrong treatment too quickly may close doors or increase side-effect risks. The waiting is still stressful, though. It can feel like sitting in an airport while every flight board says “delayed,” except the destination is your own future.

Another common experience is managing side effects that sound small on paper but loom large in daily life. A rash can make someone avoid photos. Diarrhea can turn every grocery trip into a strategic map of restroom locations. Fatigue can make a simple shower feel like a completed Olympic event. These symptoms deserve attention because they affect dignity, work, relationships, appetite, sleep, and mood.

Patients often learn that communication is treatment. Keeping a symptom diary, taking photos of rashes, recording temperature during fever, tracking bowel changes, and bringing medication lists to appointments can help the care team act faster. It is also useful to ask, “At what point should I call?” before a side effect happens. Clear thresholds reduce panic later.

Caregivers have their own learning curve. They may organize pillboxes, drive to appointments, handle insurance calls, or notice subtle changes the patient minimizes. The best caregiver support is not nagging; it is teamwork. A simple shared checklist can prevent missed doses, forgotten labs, and the classic household mystery of “Who moved the anti-nausea medicine?”

Financial and insurance experiences can also shape treatment. Targeted drugs may be expensive, and prior authorization can be slow. Patients should ask about manufacturer assistance programs, foundation grants, social workers, oncology financial navigators, and specialty pharmacy support. Money stress is not a side effect listed in every drug guide, but it is real.

Finally, many patients describe targeted therapy as living scan to scan. Good results bring relief, but the next scan date can restart anxiety. This is normal. Helpful coping strategies may include counseling, lung cancer support groups, exercise approved by the care team, breathing techniques, spiritual care, or simply having one person who can listen without trying to fix everything. Targeted therapy treats a tumor pathway; people still need care for the whole human being attached to it.

When to call the oncology team

Patients should contact their oncology team promptly for fever, severe diarrhea, dehydration, worsening shortness of breath, new or severe cough, chest pain, fainting, yellowing of the skin or eyes, confusion, sudden swelling, uncontrolled vomiting, signs of infection, severe rash, vision changes, or any symptom that feels alarming. Emergency symptoms should be handled as emergencies, not saved for the next appointment.

It is also important not to stop targeted therapy without medical guidance unless the care team has given specific instructions. Some side effects require holding the drug, but that decision should be coordinated with the oncology team whenever possible.

Conclusion

Targeted therapy for lung cancer has transformed treatment for many people with NSCLC by matching specific tumor biomarkers with specific drugs. EGFR, ALK, ROS1, BRAF, MET, RET, NTRK, KRAS, HER2, and angiogenesis-related targets each require different treatment strategies and different side-effect monitoring. The most important first step is comprehensive biomarker testing, followed by a treatment plan tailored to the patient’s cancer biology and personal health needs.

Targeted therapy can be powerful, but it is not magic, and it is not side-effect free. Skin changes, diarrhea, fatigue, swelling, liver test changes, blood pressure problems, and rare lung or heart complications all deserve attention. The best outcomes often come from a partnership: smart testing, careful drug selection, early side-effect management, honest communication, and a care team that treats the personnot just the mutation.